Nasdaq
$10.24▲ 0.54%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $715.5MShares out 69.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
41- 1d agoAfter-hours26.10.24 08:193Ownership#●●●
Helus Pharma Inc.
Executive Grant Froese of Helus Pharma Inc. has filed a Form 3 to disclose his initial beneficial ownership of securities. This filing serves as the reporting person's first statement of ownership.…more
$10.24+0.54%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 1d agoAfter-hours26.10.24 08:163Ownership
Helus Pharma Inc.
Director Eric Hoskins of Helus Pharma Inc. has filed a Form 3 to report his initial beneficial ownership of company securities. This filing serves as the official disclosure of the insider's equity holdings.…more
$10.24+0.54%vs prev closeView filingShare - 1d agoAfter-hours26.10.24 08:133Ownership
Helus Pharma Inc.
Mark Lawson, an executive at Helus Pharma Inc., has filed a Form 3 to report his initial beneficial ownership of company securities. This filing serves as the official disclosure of the insider's equity holdings.…more
$10.24+0.54%vs prev closeView filingShare
40 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoAfter-hours26.10.22 05:10#●●●#●●●
Helus Pharma Provides Clinical Program Updates
Helus Pharma announced that topline data for its Phase 3 MDD study of HLP003 is on track for release in Q4 2026. Additionally, the company plans to initiate a Phase 2 monotherapy study for its GAD treatment, HLP004, in Q1 2027.…more
$10.24+0.54%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.15Pre-market26.10.15 20:30
●●●●●●●● ●●●●● ●●●●●●
Helus Pharma has appointed CNS drug development expert Dr. Suresh Durgam to its Board of Directors. This move aims to strengthen the company's clinical development and regulatory strategy as it advances its pipeline toward potential commercialization.…more
$10.24+0.54%vs prev close - 10.8Pre-market26.10.08 20:30
●●●●●●●● ●●●●● ●●●●●●
Helus Pharma will hold an investor presentation on October 21 to discuss the development progress of its clinical-stage drug candidates for depression and anxiety. The event will feature insights from executive leadership and key opinion leaders regarding the company's therapeutic pipeline.…more
$10.24+0.54%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report